Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | PPARG | P37231 | 3/20 | 0.67 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.67 |
| ▸ | RXRA | P19793 | 2/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.67 |
| ▸ | F7 | P08709 | 3/20 | 0.57 |
| ▸ | F3 | P13726 | 3/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814940 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL5296481 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL9797172 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL13749756 | 0.93 | — | — | |
| SCHEMBL38661876 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL9463025 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL18555769 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL4804537 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL9463022 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL4804548 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP19A1MAPTPPARGOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4569012-A1 | EFFICIENT SYNTHESIS OF VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | University of Utah Research Foundation (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035945-A1 | EFFICIENT SYNTHESIS OF VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035945-A1 | EFFICIENT SYNTHESIS OF VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | WO | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-RE43632-E1 | 1,3-propane diol esters and ethers and methods for their use in drug delivery | SCARISTA, LTD. (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20120035250-A1 | PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING | PHENOMENOME DISCOVERIES INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035250-A1 | PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING | PHENOMENOME DISCOVERIES INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| WO-2010071988-A1 | PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING | PHENOMENOME DISCOVERIES INC. (CA) | 2010-07-01 | — | — | WO | disclosed |
| US-RE40546-E1 | 1,3-Propane diol esters and ethers and methods for their use in drug delivery | SCARISTA, LTD. (GB) | 2008-10-21 | — | — | US | disclosed |
| US-RE40480-E1 | 1,3-Propane diol esters and ethers and methods for their use in drug delivery | SCARISTA LIMITED (GB) | 2008-09-02 | — | — | US | disclosed |
| US-6555700-B1 | Bioactives (drugs, nutrients) in a form in which they are lipophilic so that they can pass lipid barriers (membranes, skin etc.) in the body readily; glycerides of esterified, aminated or etherified bioactives; side effect reduction | SCOTIA HOLDINGS PLC (GB) | 2003-04-29 | — | — | US | disclosed |
| WO-1998040059-A1 | UNSATURATED FATTY ACID ANHYDRIDES FOR USE IN THERAPY | SCOTIA HOLDINGS PLC (GB) | 1998-09-17 | — | — | WO | disclosed |
| EP-0823889-A1 | 1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS | SCOTIA HOLDINGS PLC (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034846-A1 | 1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS | SCOTIA HOLDINGS PLC (GB) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035250-A1 | PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING | PHOSPHO1, SGMS2, MBOAT1 | ALDH1A1 1960/4885CYP19A1 399/4885MAPT 158/4885 |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885CYP19A1 1273/4885MAPT 2665/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885CYP19A1 1273/4885MAPT 2665/4885 |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885CYP19A1 1273/4885MAPT 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.